Nektar Management to Present at Upcoming Investor Conferences

Rhea-AI Summary

Nektar Therapeutics (NKTR) has announced its management's participation in two upcoming investor conferences. The first is the H.C. Wainwright 26th Annual Global Investment Conference in New York City on September 9, 2024 at 3:00 p.m. ET. The second is the Stifel Virtual Immunology and Inflammation Summit on September 17, 2024 at 12:30 p.m. ET.

Both presentations will be accessible via webcast through the Investor Events section of Nektar's website. The webcasts will remain available for replay until October 9, 2024 and October 17, 2024, respectively, allowing investors and interested parties to access the information even after the live events.

SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:

• H.C. Wainwright 26th Annual Global Investment Conference in New York City on Monday, September 9, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time
• Stifel Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024 at 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time

The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. The webcasts will be available for replay until October 9, 2024 and October 17, 2024, respectively.

About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contact:

For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661

For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302236329.html

SOURCE Nektar Therapeutics

FAQ

When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright Global Investment Conference?

Nektar Therapeutics (NKTR) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time in New York City.

What is the date and time of Nektar's (NKTR) presentation at the Stifel Virtual Immunology and Inflammation Summit?

Nektar Therapeutics (NKTR) is scheduled to present at the Stifel Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024 at 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time.

How can investors access Nektar's (NKTR) presentations at the upcoming conferences?

Investors can access Nektar's (NKTR) presentations via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events.

Until when will the webcasts of Nektar's (NKTR) presentations be available for replay?

The webcast for the H.C. Wainwright conference will be available for replay until October 9, 2024, and the webcast for the Stifel summit will be available until October 17, 2024.